Tevogen Bio Holdings Inc. (TVGN)
NASDAQ: TVGN · Real-Time Price · USD
1.070
+0.060 (5.94%)
At close: May 5, 2025, 4:00 PM
1.050
-0.020 (-1.87%)
After-hours: May 5, 2025, 7:10 PM EDT

Company Description

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.

The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients.

It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas.

The company was founded in 2020 and is headquartered in Warren, New Jersey.

Tevogen Bio Holdings Inc.
Tevogen Bio Holdings logo
Country United States
Founded 2020
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Ryan Saadi

Contact Details

Address:
15 Independence Boulevard, Suite #410
Warren, New Jersey 07059
United States
Phone 877 838 6434
Website tevogen.com

Stock Details

Ticker Symbol TVGN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860871
CUSIP Number 88165K101
ISIN Number US88165K1016
Employer ID 98-1597194
SIC Code 2836

Key Executives

Name Position
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. Co-Founder, Chief Executive Officer and Chairperson
Kirti Desai CPA Chief Financial Officer
Dr. Neal Flomenberg M.D. Chief Scientific Officer and Global Research & Development Lead
Stephen Chen M.B.A. Chief Technical Officer
Mittul Mehta Chief Information Officer and Head of Tevogen.ai
Tapan V. Shah Head of Investor Relations and Corporate Development
Sadiq Khan M.B.A. Chief Commercial Officer
David E. Banko CPA Global Head of Government Affairs and Patient Access

Latest SEC Filings

Date Type Title
May 2, 2025 EFFECT Notice of Effectiveness
May 1, 2025 S-8 Securities to be offered to employees in employee benefit plans
Apr 30, 2025 POS AM Post-Effective amendments for registration statement
Apr 30, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025 DEF 14A Other definitive proxy statements
Apr 25, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025 8-K Current Report
Apr 17, 2025 8-K Current Report
Apr 2, 2025 10-K Annual Report
Apr 1, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405